Merck 2014 Annual Report Download - page 122

Download and view the complete annual report

Please find page 122 of the 2014 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 271

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200
  • 201
  • 202
  • 203
  • 204
  • 205
  • 206
  • 207
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • 214
  • 215
  • 216
  • 217
  • 218
  • 219
  • 220
  • 221
  • 222
  • 223
  • 224
  • 225
  • 226
  • 227
  • 228
  • 229
  • 230
  • 231
  • 232
  • 233
  • 234
  • 235
  • 236
  • 237
  • 238
  • 239
  • 240
  • 241
  • 242
  • 243
  • 244
  • 245
  • 246
  • 247
  • 248
  • 249
  • 250
  • 251
  • 252
  • 253
  • 254
  • 255
  • 256
  • 257
  • 258
  • 259
  • 260
  • 261
  • 262
  • 263
  • 264
  • 265
  • 266
  • 267
  • 268
  • 269
  • 270
  • 271

117GROUP MANAGEMENT REPORT → REPORT ON ECONOMIC POSITION → Life Science
LIFE SCIENCE →
SALES COMPONENTS BY REGION – 2014
€ million / change in % Sales Organic growth
Exchange rate
effects
Acquisitions /
divestments Total change
Europe 1,036.3 2.7 0.3 – 0.4 2.6
North America 725.0 3.7 0.2 – 2.0 1.9
Emerging Markets 673.1 9.1 – 4.2 – 0.1 4.8
Rest of World 248.1 2.5 – 7.8 – 0.4 – 5.7
Life Science division 2,682.5 4.5 – 1.7 – 0.7 2.1
The sales performance of each of the division’s three business ar-
eas varied in 2014. Whereas the two top-selling business areas,
Lab Solutions and Process Solutions, generated higher sales due to
price and volume increases, sales of the Bioscience business area
nearly remained stable.
The Process Solutions business area, which markets products
and services for the pharmaceutical production value chain, gen-
erated sales organic growth of 8.9 %, which was the highest rate
within the Life Science division. This increase resulted mainly
from higher demand from the biotech industry for purification
and sterilization products as well as filtration systems. Taking into
account negative foreign exchange effects of –1.1 % as well as the
–1.8 % decrease in sales due to the divestment of the Discovery
and Development Solutions business field, sales amounted to
€1,187 million in 2014 (20131: €1,121 million). Process Solutions
thus accounted for 44 % of divisional sales (2013: 43 %).
Sales by Lab Solutions, which accounted for a 41 % share (2013:
42 %) of divisional sales, generated organic sales growth of 1.9 %
with its broad range of products for researchers and scientific lab-
oratories. Currency headwinds of – 2.4 % led to slightly lower sales
of €1,093 million (20131: €1,099 million) for the business area.
Higher sales were primarily achieved by the Lab Water and Bio-
monitoring business fields.
The Bioscience business area, which primarily markets prod-
ucts and services for academic and pharmaceutical research labo-
ratories, recorded a slight organic sales decline of – 0.5 %. Includ-
ing adverse foreign exchange effects of – 0.9 %, sales amounted
to €402 million (20131 : €408 million). Here, for instance, lower
demand for antibodies dampened sales. However, this was largely
mitigated by higher demand from diagnostic laboratories for cell
analysis products. At 15 %, the business area’s share of divisional
sales was unchanged in 2014.
1 Previous year's figures have been adjusted owing to an internal reorganization.